Home

Mineralys Therapeutics, Inc. - Common Stock (MLYS)

16.87
+0.14 (0.84%)

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet needs in the treatment of cardiovascular and metabolic diseases

The company specializes in discovering and commercializing novel therapeutics that target mineralocorticoid receptors, a pathway that plays a significant role in regulating blood pressure and fluid balance. Through its cutting-edge research and development efforts, Mineralys aims to improve patient outcomes and enhance quality of life by providing effective solutions for conditions related to hypertension and related disorders.

SummaryNewsPress ReleasesChartHistoricalFAQ
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. (“Mineralys” or “the Company”) (NASDAQ: MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MLYS.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · September 20, 2024
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. (“Mineralys” or “the Company”) (NASDAQ: MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/MLYS.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · September 12, 2024
MLYS Investors Have Opportunity to Join Mineralys Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. (“Mineralys” or “the Company”) (NASDAQ: MLYS) for violations of the securities laws.
By Schall Law · Via GlobeNewswire · September 9, 2024
Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer’s Disease, today announced the appointment of Adam Levy to its Board of Directors (the “Board”). Mr. Levy brings executive, financial and operational leadership experience in biopharmaceuticals.
By Praxis Bioresearch, Inc. · Via GlobeNewswire · September 19, 2023
There's a Lot to Love About Mineralys' Valentine's Day IPO
MLYS added 20% more shares to IPO funding, which goes live on 2/14. The bump secured liquidity to stabilize development, improving market cap to $683 million
Via MarketBeat · February 13, 2023